GlassScriptPhysician profile
Ather Zafar
NPI 1649470592
$3,256.83
in general payments reported to CMS, 2019-2025
23 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $197 · 2021: $125 · 2022: $271 · 2023: $389 · 2024: $537 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.26 |
| Education | $141.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $725.44 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $525.76 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $333.04 | 2021-2024 | |
| Amgen INC. | $271.83 | 2019-2024 | Procysbi |
| Travere Therapeutics, INC. | $183.62 | 2024-2025 | Filspari |
| Fresenius USA Marketing, INC. | $125.97 | 2019-2024 | Velphoro |
| Outset Medical INC | $124.20 | 2023 | |
| Akebia Therapeutics INC | $119.88 | 2019-2025 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $112.06 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $105.54 | 2022-2024 | Rayaldee |
| Vifor Pharma, INC. | $95.18 | 2019-2023 | Veltassa |
| Mallinckrodt Enterprises LLC | $76.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.43 | 2024-2025 | |
| Ardelyx, INC. | $62.78 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $51.20 | 2023-2025 | Tarpeyo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $50.80 | 2021-2023 | Krystexxa |
| Genentech USA, INC. | $50.01 | 2025 | Gazyva |
| Scpharmaceuticals INC. | $47.43 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.03 | 2024-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $37.57 | 2024-2025 | |
| Novo Nordisk INC | $15.48 | 2025 | Ozempic, Rybelsus |
| Arbor Pharmaceuticals, INC. | $14.97 | 2020 | |
| Aurinia Pharma U.S., INC. | $12.97 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ather Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.